Clinical Pipeline

We have a rich pipeline of products

Our partners are advancing several compounds in clinical trials that were the outcome of previous drug discovery collaborations with Astex including three drugs that have now been approved. The responsibility for developing these products is with our partners.

Discovery	Phase 1	Phase 2	Phase 3	Marketed

Kisqali^® (ribociclib)

CDK4/6 inhibitor (Oncology)
Partner: Novartis

.	.	.	.	.

Balversa^® (erdafitinib)

FGFr inhibitor (Oncology)
Partner: Janssen

.	.	.	.	.

Truqap^® (capivasertib)

PKB/Akt Inhibitor (Oncology)
Partner: AstraZeneca

.	.	.	.	.

KRAS Oncogene (Oncology)

Partner: MSD and Taiho

G12C:

.	.	.	.

Other mutants:

.

Beroterkib (ASTX029)

Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
Partner: Mosaic Therapeutics

.	.	.

ASTX295

Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
Partner: Mosaic Therapeutics

.	.

SHP2 (Oncology)

Partner: MSD and Taiho

.	.

P53 (Oncology)

Partner: MSD

.

Partnered products and programs

Proprietary Product and Program

Below is our pipeline of proprietary investigational compounds that are currently in various stages of clinical development.

For more information on the pipeline of investigational compounds generated by Astex that are currently in clinical development at Taiho Oncology Inc., please follow the link here

Discovery	Phase 1	Phase 2	Phase 3	Marketed

Tolinapant (ASTX660)

Antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP) (T-cell Lymphomas)

.	.

For more information on the pipeline of products being developed globally at Otsuka, please follow the link here